Featured Press Releases

Innocan Pharma submits Investigational New Animal Drug application to FDA

Innocan Pharma submits Investigational New Animal Drug application to FDA's Veterinary Center.

ARTHEx Biotech doses first patient in Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1

ARTHEx Biotech doses first patient in Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1

  • 18 Oct 2024

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative...

AdvanCell Proudly Announces $18M in MRFF Frontiers Initiative Funding to Advance Targeted Alpha Therapy for Defeating Prostate Cancer

AdvanCell Proudly Announces $18M in MRFF Frontiers Initiative Funding to Advance Targeted Alpha Therapy for Defeating Prostate Cancer

Fresenius Expands Biosimilars Portfolio with Denosumab Launch in the U.S

Fresenius Expands Biosimilars Portfolio with Denosumab Launch in the U.S

NurtureBio Launched Breast Milk–Inspired Synbiotic to Help Babies with Gut Issues

NurtureBio Launched Breast Milk–Inspired Synbiotic to Help Babies with Gut Issues

Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

Virax Biolabs CEO James Foster Updates Shareholders Following the Fiscal 2026 Annual Report and Commercial Supply Agreement with Fosun Diagnostics

Virax Biolabs CEO James Foster Updates Shareholders Following the Fiscal 2026 Annual Report and Commercial Supply Agreement with Fosun Diagnostics

  • Virax BioLabs Group Limited
  • 16 Jul 2026
Children

Children's Hospital of Philadelphia Initiative Substantially Increases Naloxone Co-Prescribing When Prescribing Outpatient Opioids

  • Children's Hospital of Philadelphia
  • 16 Jul 2026
Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

  • Hologic, Inc.
  • 14 Jul 2026
Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

  • Merck
  • 14 Jul 2026
BioMarin

BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia Accepted by the U.S. Food and Drug Administration

  • BioMarin Pharmaceutical Inc.
  • 13 Jul 2026
FDA Approves Expanded Indication for Octapharma USA

FDA Approves Expanded Indication for Octapharma USA's wilate® for Prophylaxis of von Willebrand Disease in Children Younger Than 6 Years

  • Octapharma
  • 10 Jul 2026
The Digital Pharma Advances Conference 2026

Most Popular
July   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.